Cargando…

Stereotactic body radiation therapy use for high risk prostate cancer in the United States

Detalles Bibliográficos
Autores principales:	Patel, Sagar A., Switchenko, Jeffrey M., Kishan, Amar U., Jani, Ashesh B., Royce, Trevor J., Fischer-Valuck, Benjamin W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8116349/ https://www.ncbi.nlm.nih.gov/pubmed/33188271 http://dx.doi.org/10.1038/s41391-020-00300-5

Ejemplares similares

Stereotactic body radiotherapy versus conventional/moderate fractionated radiation therapy with androgen deprivation therapy for unfavorable risk prostate cancer
por: Patel, Sagar A., et al.
Publicado: (2020)

Stereotactic Body Radiotherapy for Prostate Cancer
por: Parikh, Neil R., et al.
Publicado: (2020)

Editorial: Stereotactic body radiotherapy for prostate cancer
por: Kishan, Amar U., et al.
Publicado: (2022)

The Association of Radiation Dose With Overall Survival for Patients Treated With Prostate Stereotactic Body Radiation Therapy
por: Waters, Michael R, et al.
Publicado: (2023)

Trends in Use and Comparison of Stereotactic Body Radiation Therapy, Brachytherapy, and Dose-Escalated External Beam Radiation Therapy for the Management of Localized, Intermediate-Risk Prostate Cancer
por: Nguyen, Kevin A., et al.
Publicado: (2020)

Analysis of Radiation Facility Volume and Survival in Men With Lymph Node–Positive Prostate Cancer Treated With Radiation and Androgen Deprivation Therapy
por: Patel, Sagar A., et al.
Publicado: (2020)

Influence of Timing Between Androgen Deprivation Therapy and External Beam Radiation Therapy in Patients With Localized, High-Risk Prostate Cancer
por: McCall, Neal S., et al.
Publicado: (2021)

Radiation Facility Volume and Survival for Men With Very High-Risk Prostate Cancer Treated with Radiation and Androgen Deprivation Therapy
por: Sebastian, Nikhil, et al.
Publicado: (2023)

Magnetic Resonance Image Guided Stereotactic Body Radiation Therapy to the Primary Renal Mass in Metastatic Renal Cell Carcinoma
por: Rudra, Soumon, et al.
Publicado: (2019)

Rectal Radiation Dose and Clinical Outcomes in Prostate Cancer Patients Treated With Stereotactic Body Radiation Therapy With and Without Hydrogel
por: Kundu, Palak, et al.
Publicado: (2022)

Ablative Radiotherapy in Prostate Cancer: Stereotactic Body Radiotherapy and High Dose Rate Brachytherapy
por: Ma, Ting Martin, et al.
Publicado: (2020)

Magnetic Resonance Imaging Guidance Mitigates the Effects of Intrafraction Prostate Motion During Stereotactic Body Radiotherapy for Prostate Cancer
por: Hegde, John V, et al.
Publicado: (2018)

Clinical Assessment of Prostate Displacement and Planning Target Volume Margins for Stereotactic Body Radiotherapy of Prostate Cancer
por: Levin-Epstein, Rebecca, et al.
Publicado: (2020)

Gantry-Mounted Linear Accelerator–Based Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer
por: Dang, Audrey T., et al.
Publicado: (2019)

Cost Comparison From a Patient Perspective for Intracranial Stereotactic Radiation Therapy
por: Prasad, Rahul N., et al.
Publicado: (2021)

Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer
por: Ahmed, Kamran A., et al.
Publicado: (2013)

Dysuria Following Stereotactic Body Radiation Therapy for Prostate Cancer
por: Janowski, Einsley-Marie, et al.
Publicado: (2015)

Proctitis following stereotactic body radiation therapy for prostate cancer
por: Joh, Daniel Y, et al.
Publicado: (2014)

Recall of reactive cutaneous capillary endothelial proliferation (RCCEP) induced by stereotactic body radiation therapy (SBRT) in a patient with lung squamous cell carcinoma
por: Ma, Rong, et al.
Publicado: (2022)

Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer
por: Ju, Andrew W, et al.
Publicado: (2013)

Stereotactic body radiation therapy for the primary treatment of localized prostate cancer
por: Oliai, Caspian, et al.
Publicado: (2012)

Stereotactic Body Radiation Therapy for Low- to Intermediate-risk Prostate Adenocarcinoma
por: Jeong, Bae-Kwon, et al.
Publicado: (2015)

Potency preservation following stereotactic body radiation therapy for prostate cancer
por: Obayomi-Davies, Olusola, et al.
Publicado: (2013)

Bothersome Hematospermia Following Stereotactic Body Radiation Therapy for Prostate Cancer
por: Shah, Sarthak, et al.
Publicado: (2021)

Salvage Prostate Stereotactic Body Radiation Therapy After Definitive Cryoablation
por: Lischalk, Jonathan W., et al.
Publicado: (2021)

Prostate-Specific Antigen Bounce Following Stereotactic Body Radiation Therapy for Prostate Cancer
por: Vu, Charles C., et al.
Publicado: (2014)

Radiobiological mechanisms of stereotactic body radiation therapy and stereotactic radiation surgery
por: Kim, Mi-Sook, et al.
Publicado: (2015)

A Brief Review of Low-Dose Rate (LDR) and High-Dose Rate (HDR) Brachytherapy Boost for High-Risk Prostate
por: Fischer-Valuck, Benjamin W., et al.
Publicado: (2019)

Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial
por: Ma, Ting Martin, et al.
Publicado: (2021)

A Prospective Study of High Dose-Rate Brachytherapy or Stereotactic Body Radiotherapy of Intra-Prostatic Recurrence: Toxicity and Long Term Clinical Outcome
por: Ryg, Una, et al.
Publicado: (2022)

Obstructive voiding symptoms following stereotactic body radiation therapy for prostate cancer
por: Arscott, W Tristram, et al.
Publicado: (2014)

Editorial: The Evolving Landscape of Stereotactic Body Radiation Therapy for the Management of Prostate Cancer
por: Blacksburg, Seth R., et al.
Publicado: (2020)

Toxicity After Stereotactic Body Radiation Therapy for Prostate Cancer in Patients With Inflammatory Bowel Disease: A Multi-institutional Matched Case-Control Series
por: Juarez, Jesus E., et al.
Publicado: (2021)

Treatment Patterns and Overall Survival Outcomes Among Patients Aged 80 yr or Older with High-risk Prostate Cancer
por: Fischer-Valuck, Benjamin W., et al.
Publicado: (2022)

Rationale for Involved Field Stereotactic Body Radiation Therapy-Enhanced Intermittent Androgen Deprivation Therapy in Hormone-Sensitive Nodal Oligo-Recurrent Prostate Cancer Following Prostate Stereotactic Body Radiation Therapy
por: Carrasquilla, Michael, et al.
Publicado: (2021)

Development and Validation of a Comprehensive Multivariate Dosimetric Model for Predicting Late Genitourinary Toxicity Following Prostate Cancer Stereotactic Body Radiotherapy
por: Valle, Luca F., et al.
Publicado: (2020)

Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm(3))
por: Janowski, Einsley, et al.
Publicado: (2014)

Dosimetric Comparison and Evaluation of 4 Stereotactic Body Radiotherapy Techniques for the Treatment of Prostate Cancer
por: Seppälä, Jan, et al.
Publicado: (2016)

Reply to: Dose-escalation of radiation may improve outcomes of squamous cell carcinoma of bladder
por: Fischer-Valuck, Benjamin W., et al.
Publicado: (2019)

Sexual, irritative, and voiding outcomes, following stereotactic body radiation therapy for prostate cancer
por: Rana, Zaker, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_8mjul8tqnlues9oqd5un06ut72